{"id":"NCT01368497","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","briefTitle":"Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection","officialTitle":"Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2016-12-23","completion":"2016-12-23","firstPosted":"2011-06-08","resultsPosted":"2018-07-03","lastUpdate":"2022-05-26"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis B"],"interventions":[{"type":"DRUG","name":"Entecavir and peginterferon","otherNames":["PEGASYS, peginterferon alfa 2a, Baraclude"]}],"arms":[{"label":"Entecavir and peginterferon","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-\\<18 years old with immunotolerant chronic hepatitis B.","primaryOutcome":{"measure":"Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss & Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels â‰¤1,000 International Units (IU) Per Milliliter (mL)","timeFrame":"End of follow-up (up to 96 weeks)","effectByArm":[{"arm":"Entecavir and Peginterferon","deltaMin":0.033,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":24},"locations":{"siteCount":7,"countries":["United States","Canada"]},"refs":{"pmids":["24318082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":60},"commonTop":["Low absolute neutrophil count","ALT or AST elevation","Strep throat","Sinus infection","Neutropenia"]}}